
# Title 21— FOOD AND DRUGS
### CHAPTER 9— FEDERAL FOOD, DRUG, AND COSMETIC ACT
#### § 355a. Pediatric studies of drugs
##### (o) Prompt approval of drugs when pediatric information is added to labeling

(1) General rule

A drug for which an application has been submitted or approved under subsection (b)(2) or (j) of section 355 of this title shall not be considered ineligible for approval under that section or misbranded under section 352 of this title on the basis that the labeling of the drug omits a pediatric indication or any other aspect of labeling pertaining to pediatric use when the omitted indication or other aspect is protected by patent, or by exclusivity under clause (iii) or (iv) of section 355(j)(5)(F) of this title , clause (iii) or (iv) of section 355(c)(3)(E) of this title , or section 360cc(a) of this title , or by an extension of such exclusivity under this section or section 355f of this title .

(2) Labeling

Notwithstanding clauses (iii) and (iv) of section 355(j)(5)(F) of this title , clauses (iii) and (iv) of section 355(c)(3)(E) of this title , or section 360cc of this title , the Secretary may require that the labeling of a drug approved pursuant to an application submitted under subsection (b)(2) or (j) of section 355 of this title that omits a pediatric indication or other aspect of labeling as described in paragraph (1) include

(A) a statement that, because of marketing exclusivity for a manufacturer

(i) the drug is not labeled for pediatric use; or

(ii) in the case of a drug for which there is an additional pediatric use not referred to in paragraph (1), the drug is not labeled for the pediatric use under paragraph (1); and

(B) a statement of any appropriate pediatric contraindications, warnings, precautions, or other information that the Secretary considers necessary to assure safe use.

(3) Preservation of pediatric exclusivity and extensions

This subsection does not affect

(A) the availability or scope of exclusivity under

(i) this section;

(ii) section 355 of this title for pediatric formulations; or

(iii) section 360cc of this title ;

(B) the availability or scope of an extension to any such exclusivity, including an extension under this section or section 355f of this title ;

(C) the question of the eligibility for approval under section 355 of this title of any application described in subsection (b)(2) or (j) of such section that omits any other aspect of labeling protected by exclusivity under

(i) clause (iii) or (iv) of section 355(j)(5)(F) of this title ;

(ii) clause (iii) or (iv) of section 355(c)(3)(E) of this title ; or

(iii) section 360cc(a) of this title ; or

(D) except as expressly provided in paragraphs (1) and (2), the operation of section 355 of this title or section 360cc of this title .
